Tandem Diabetes appoints Jean-Claude Kyrillos as EVP, COO effective June 21, 2024

TANDEM DIABETES CARE INC

Kyrillos previously served as President of Diagnostics & Digital Solutions at Envista Holdings and held senior roles at Qualcomm Life, BD, and ResMed.
Annual base salary set at $450,203.73; target bonus of 60% of base salary (0-200% payout range) under Cash Bonus Plan.
Target long-term incentive of 400% of base salary in RSUs under the 2023 Long-Term Incentive Plan.
Severance agreement provides 18 months base salary continuation and full equity acceleration upon qualifying termination within change-of-control window.
Kyrillos holds a BA from Colgate University and an MBA from Harvard Business School.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jean-Claude Kyrillos

Chief Operating Officer

TNDM · TANDEM DIABETES CARE INC

Effective: 2024-06-21
Filed: June 21, 2024, 7:59 PM ET

On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jean-Claude Kyrillos was appointed as Chief Operating Officer at TANDEM DIABETES CARE INC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.

View on SEC.gov

TANDEM DIABETES CARE INC filing history →

Source: SEC EDGAR

accession 0001438133-24-000166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.